Perceive Biotherapeutics, a San Francisco, CA-based biotech company focused on technologies and therapeutics in ophthalmology, raised $78M in Series B funding.
The round was led by Johnson & Johnson Innovation – JJDC, Inc.(JJDC), with participation from Deerfield Management, Braidwell LP, the Retinal Degeneration Fund, and Catalio Capital Management, LP.
The company intends to use the funds to accelerate its progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline.
Led by CEO K. Angela Macfarlane, and President Anne Rubin, Perceive Biotherapeutics is advancing a deep and diversified pipeline of targets and treatment modalities in multiple therapeutic verticals, with lead pipeline programs in ophthalmology. Perceive Bio is advancing therapeutic programs in geographic atrophy / age-related macular degeneration, glaucoma, and additional undisclosed disease areas. The company is a resident of JLABS @ San Diego, part of Johnson & Johnson Innovation – JLABS, a global life science incubator network, providing startups with access to capital-efficient lab space, equipment, and resources, including expertise, community, and entrepreneurial programs.
FinSMEs
05/01/2023